Novavax consolidates its presence at the World Vaccine Congress and the 32nd European Congress of Clinical Microbiology and Infectious Diseases… –

  • World Vaccine Congress to present new data on combination vaccine against COVID-19 and seasonal influenza
  • Several talks and presentations are planned to provide an update on NVX-CoV2373, Novavax’s COVID-19 vaccine.

GAITHERSBURG, Maryland, April 19, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will present data from its trials on the combination vaccine against COVID-19 influenza and on the vaccine against seasonal influenza, during the World Vaccine Congress (WVC) to be held at Washington, D.C.April 18-21, 2022. In addition, the latest data on NVX-CoV2373, its protein vaccine candidate against COVID-19, will be presented at the WVC and the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Lisbon, PortugalApril 23-26, 2022. Data from eight talks and presentations, including four oral presentations, will be presented at both congresses.

The doctor Gregory M. Glenn, President of Research and Development of Novavax, said: “Our presence at these two major industry conferences shows our continued commitment to addressing the issue of COVID-19, and the advances we have made towards a vaccine. next generation anti-influenza. We look forward to sharing these updates which further demonstrate the potential of our platform. »

Main presentations of Novavax during the WVC:

Glenn, G.

How long will our immunity to COVID-19 last?
and will our vaccines continue to work
against VOCs?

panel

April 19, 2022

8:45 a.m. – 9:45 a.m. ET

Kim, D.

Monitoring the Safety of COVID-19 Vaccines
under authorization
of emergency use: challenges and lessons?

panel

April 20, 2022

12:10 – 1:10 p.m. ET

Glenn, G.

Clinical Update on Recombinant Nanoparticle Protein Subunit
Novavax’s COVID-19 vaccine in
as a booster vaccine

Oral

Session on COVID-19 and beyond – M4

April 20, 2022

12:40 – 12:00 ET

Shinde, V

NanoFlu* Vaccine Development Update
and the combined vaccine against
Novavax COVID-19 Flu

Oral

Influenza and Respiratory Illness Session – M4

April 20, 2022

12:40 p.m. – 1:10 p.m. ET

*NanoFlu identifies an influenza vaccine candidate based on recombinant hemagglutinin (HA) nanoparticles produced by Novavax. This investigational candidate was evaluated in a phase 3 controlled trial conducted during the 2019-2020 influenza season.

Key Novavax presentations during ECCMID:

Toback, S

Continued Safety and Effectiveness of the NVX-CoV2373 Vaccine
COVID-19 in the UK

Presentation No. 04525

Oral

Breaking news session on COVID vaccination

April 25, 2022

16:15 – 17:15 CET

Shinde, V

Long-term durability of polyfunctional CD4+ T cell responses
antigen-specific against homologous and deviant viruses on the
antigenic plan: results of a phase III trial of an influenza
quadrivalent recombinant nanoparticles
based on saponin-adjuvanted hemagglutinin.

Presentation No. 1197

Oral

Session Viral respiratory infections: Influenza and RSV

April 26, 2022

11:00 – 12:00 CET

Áñez, G

Safety, efficacy and performance of an adjuvanted vaccine based on
recombinant SARS-CoV-2 spike protein (NVX-CoV2373)
in a phase III trial in adolescents (PREVENT-19)

Presentation No. 04455

Attach

Session 12g. Vaccine development, trials, efficacy, policy

April 25, 2022

12:00 – 13:00 CET

Áñez, G

Molecular epidemiology of SARS-CoV-2 strains

identified in a phase III efficacy and safety trial
of the NVX-CoV2373 (PREVENT-19) vaccine to
United States and Mexico.

Presentation No. 00284

Attach

Session 12l. Evolution, variants and impact of the virus

April 25, 2022

12:00 – 13:00 CET

Beyhaghi, H

Declared pregnancies and associated results within the framework
of the clinical development program of the vaccine
NVX-CoV2373 COVID-19.

Presentation No. 01705

Attach

Session 12g. Vaccine development, trials, efficacy, policy

April 25, 2022

12:00 – 13:00 CET

Marchese, A.

COVID-19 Vaccine Receptivity and Preferences Among
the “vaccination hesitant”.

Presentation No. 04362

Attach

Session 12g. Vaccine development, trials, efficacy, policy

April 25, 2022

12:00 – 13:00 CET

For more information or to register, visit the websites of the World Vaccine Congress Washington 2022 and 32nd European Congress of Clinical Microbiology and Infectious Diseases.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved global health through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The Company’s patented recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address pressing global health needs. NVX-CoV2373, the company’s COVID-19 vaccine, has been cleared by multiple regulatory agencies globally, including conditional marketing authorization from the European Commission and the Organization World Health. The vaccine is also under review by multiple regulatory agencies around the world. In addition to its COVID-19 vaccine, Novavax is currently evaluating a combination COVID seasonal influenza vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and its experimental quadrivalent influenza vaccine, previously called NanoFlu. These vaccine candidates incorporate Novavax’s saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

To learn more, visit www.novavax.com and follow the company on LinkedIn.

contacts:
Investors
Erika Schultz | 240-268-2022
ir@novavax.com

Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
media@novavax.com

Novavax Logo

Leave a Comment